In This Section
2024 Saul Hertz, MD Award Winner: Michael Hofman, MBBS
The Saul Hertz, MD Award is a lifetime achievement award, recognizing individuals who have made outstanding contributions to radionuclide therapy.
In 2024, the award was presented to Michael S. Hofman, MBBS.
Professor Hofman is a nuclear medicine physician, physician-scientist and Director of the Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC) at the Peter MacCallum Cancer Centre in Melbourne. He previously completed a research fellowship at Guy's & St Thomas' in London. Dr Hofman led landmark research contributing to global adoption of PSMA PET/CT and PSMA radioligand therapy as new standards-of-care for imaging and targeted treatment for men with prostate cancer. His research contributed to FDA approval, reimbursement and a $2.1b investment by Novartis. He maintains a broad research interest in novel radiopharmaceuticals for imaging and therapy (theranostics) in oncology, collaborating widely to perform Phase I, II and III clinical trials in areas of unmet need ranging from first-in-human evaluation of novel radiopharmaceuticals to conducting large multi-center randomized clinical trials.
Through his involvement on the scientific committee of the Australasian Radiopharmaceutical Trials Network (ArtNet) he has established a network of more than 10 centers around Australia with multi-disciplinary expertise culminating in two first author landmark clinical trials published in The Lancet (ProPSMA ‘20 and TheraP trial ‘21; >1500 citations). He has delivered keynote scientific and educational presentations at leading oncology, urology and nuclear medicine conferences (ESMO, ASCO, ASCO GU, EAU, SNMMI, EANM) giving over 200 talks in more than 25 countries. Professor Hofman has active grants totaling more than $55 million dollars and he currently leads a US$10 million collaboration focused on development of 21st Century therapies for lethal forms of prostate cancer.
Professor Hofman has a leading academic track record for his specialty, with over 250 peer reviewed manuscripts (40 cited more than 100 times) and book chapters. He has received numerous awards including the ACTA Clinical Trial of the Year Award 2021, and awards for best scientific research at SNMMI, EANM, WFNMB and ANZSNM conferences. He was the co-chair of the 4th World Theranostic World Congress in 2016. Elected memberships include the International Cancer Imaging Society (2015), Nuclear Society of Singapore (2023) and the Australian Academy of Health and Medical Sciences (2023). He was a member of the oncology subcommittee of the Australian MBS Review achieving expanded equitable access to PET funding in Australia.
 |
|
| Michael Hofman, MBBS |